Results 161 to 170 of about 53,097 (209)

Future Prospects of Imatinib in Advanced Pulmonary Hypertension Management. [PDF]

IUBMB Life
Davì F, Mangione S, Iaconis A, Genovese T, Tranchida N, Cuzzocrea S.   +5 more
europepmc   +1 more source

Targeting the Unmet Need in Gastrointestinal Stromal Tumors: A Contemporary Review of Investigational Clinical Trials and Therapeutic Landscape. [PDF]

Pharmaceuticals (Basel)
Belančić A, Prejac J, Golčić M, Adžić G, Katić A, Kocić L, Kovač Peić A, Librenjak N, Belev B, Mikolašević I, Pleština S.   +10 more
europepmc   +1 more source

A high-throughput modular microfluidic platform for versatile functional assays at single-cell level. [PDF]

Microsyst Nanoeng
Shao N, Mai J, Godin B, Liu X.
europepmc   +1 more source

Pulmonary Arterial Hypertension Risk With BCR-ABL Tyrosine Kinase Inhibitors: Refining Risk With Nationwide Data. [PDF]

Circulation
Garry JD, Brittain EL.
europepmc   +1 more source

Hypereosinophilic endocarditis presenting with intracardiac mass and severe mitral regurgitation: a case report of FIP1L1-PDGFRA positive myeloid neoplasm. [PDF]

Eur Heart J Case Rep
Rao NS, Biswas A, Kothari SS, Vyas P, Kanabar K.   +4 more
europepmc   +1 more source

Enhancing tyrosine kinase inhibitor sensitivity by restoring IKAROS activity on GLUT1 expression and glycolysis in Philadelphia chromosome-positive acute lymphoblastic leukemia. [PDF]

Leukemia
Zhang L, Han Q, Xiang H, Lapalombella R, Eisfeld AK, Hanel WG, Brammer JE, Mims AS, Woyach JA, Song C, Ge Z.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Imatinib

Drugs, 2001
Imatinib inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome (Ph+) in chronic myeloid leukaemia (CML). Complete haematological responses were achieved in 88% of patients and major cytogenetic responses were detected in 49% of patients with chronic phase CML treated with oral imatinib 400 mg/day in a multicentre noncomparative ...
K, Lyseng-Williamson, B, Jarvis
openaire   +2 more sources

Imatinib and Hyperlipidemia

New England Journal of Medicine, 2005
To the Editor: We report on a series of nine patients with hyperlipidemia and either chronic myeloid leukemia or the hypereosinophilic syndrome, in eight of whom plasma lipid levels normalized within one month after imatinib therapy (at a dose of 400 mg daily) was started. All nine patients had hypercholesterolemia (mean plasma total cholesterol level,
GOTTARDI M, MANZATO, ENZO, GHERLINZONI F.   +2 more
openaire   +3 more sources

Imatinib Mesylate

2014
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Badraddin M H, Al-Hadiya, Ahmed H H, Bakheit, Ahmed A, Abd-Elgalil   +2 more
openaire   +2 more sources

Imatinib Mesylate

2009
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire   +6 more sources